SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

Novel and potentially groundbreaking therapeutic strategy

10-Jul-2024 - SciRhom GmbH announced the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including ...

Using artificial intelligence to discover therapeutic antibodies

Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics

21-Dec-2023 - Antibodies are an important tool in the human immune system’s arsenal against disease. They attach to bacteria, viruses, fungi, or toxins, marking them for destruction or removal from the body.It is this ability to recognise and mark foreign and harmful molecules and organisms that allows ...

HTGF invests in biotech start-up adivo

Pet therapeutic antibody firm adivo announces closure of seed-financing round

22-Aug-2018 - German biotech company adivo specializing in generating species-specific therapeutic antibodies for companion animals announces that it received a seed financing from three investors. The adivo team aims to address high medical needs in dogs including cancer and chronic inflammation, with the ...

LDC opens branch in Munich

Focus on discovery of therapeutic antibodies

24-Apr-2018 - The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emphasis will be on the development of therapeutic antibodies. LDC Biologics will produce, optimise ...

MorphoSys Strengthens Patent Position on MOR202 Program

25-Jan-2012 - MorphoSys AG announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled ...

LEUKOCARE signs cooperation agreement with Sterigenics

19-Nov-2010 - LEUKOCARE AG announced the signing of a cooperation agreement with Sterigenics. As part of this cooperation, LEUKOCARE plans to use their Stabilizing and Protecting Solutions (SPS) technology together with Sterigenics’ irradiation expertise in order to establish new sterilization procedures for ...

BIOTECHNICA 2010 with new focus topics

21-Sep-2010 - BIOTECHNICA 2010 is open for business in Hannover from 5 to 7 October, with new focus topics and more wide-ranging coverage. Europe’s leading biotech and life sciences event focuses on biotech applications in the fields of medicine, pharmaceuticals, food, agriculture, manufacturing industry and ...

Scil Proteins Appoints Advisory Board

12-Aug-2010 - Scil Proteins announced that it has completed the formation of its advisory board (AB). The AB is comprised of Dr. Andreas Menrad, Dr. Jürgen Wahl and Rainer Kroell. Andreas Menrad, PhD, is currently the Vice President of Antibody Therapeutics at Genzyme’s European Research site in Cambridge, ...

MorphoSys Announces Clinical Milestone from Strategic Alliance

Second Clinical Milestone in 2010

05-Jul-2010 - MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. The news represents the second HuCAL-derived antibody to ...

GENEART and MorphoSys Successfully Cooperate in HuCAL PLATINUM Project

19-Dec-2008 - GENEART and MorphoSys announced their successful cooperation in the HuCAL PLATINUM® project. The application of GENEART's proprietary sequence design software GeneOptimizer® and production of significant parts of the antibody library allowed GENEART to make a large contribution to this project, ...